|
Genetic Analysis of Gray Platelet Syndrome Clinical Trials Info presented on Clinical Trials Search isn't intended to be a substitute for certified health advice, travels to or treatment by using a genuine physician. We are not physicians. Always consult your dr. on Genetic Analysis of Gray Platelet Syndrome conditions. Clinical Trials Search.org is a site committed to listing clinical research studies in human subjects. Genetic Analysis of Gray Platelet Syndrome Clinical research trials and Genetic Analysis of Gray Platelet Syndrome health trials occur in hundreds of cities throughout the U.S.A.. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials typically assess the effectivity of new drugs. The propose of the studies / undertakings is to resolve certain human health questions. Clinical trials are a popular means for physicians, government agencies, and private sector companies to locate treatments for all sorts of conditions, including Genetic Analysis of Gray Platelet Syndrome. Genetic Analysis of Gray Platelet Syndrome Clinical Trials and other clinical trials permit volunteers to acquire medical treatment choices before they are available to the masses. Some times the test subjects obtain professional assistance for free, and every now and again they are compensated for their time. Sometimes there is a cost for a Genetic Analysis of Gray Platelet Syndrome clinical trial. Participants oftentimes recieve the most expert healthcare available for their Genetic Analysis of Gray Platelet Syndrome condition. Hazards are a reality, however, and can include extra or frequent physician visits, health risks (potentially life-endangering), and/or the treatment being uneffective. Trials are federally governed with rigorous guidelines to protect clinical trials subjects.
|
|
|
|
|
|
|
Home > "G" Clinical Trials Conditions > Genetic Analysis of Gray Platelet Syndrome  Genetic Analysis of Gray Platelet Syndrome
Genetic Analysis of Gray Platelet Syndrome
For Condition: Myelofibrosis,Genetic Linkage
Status: Recruiting
Sponsor(s): National Human Genome Research Institute (NHGRI) ,
Synopsis: This study will identify and characterize the gene or genes responsible for Gray Platelet syndrome (GPS). Platelets are small blood cells that stick on injured blood vessels to form a plug and stop bleeding. When a blood vessel is injured (like a cut on a finger), platelets release the proteins stored in their sacs to help form a blood clot. Patients with GPS bleed longer than other people because their platelets lack some of these protein-carrying sacs. Platelets without sacs look pale gray under the microscope rather than pink, giving the syndrome its name. Except for rare patients with severe hemorrhage, the bleeding tendency in GPS is usually mild to moderate, with patients experiencing easy bruising, nosebleeds, and, in women, excessive menstrual bleeding. Patients with GPS and members of their family with GPS may be eligible for this study. Participants will provide a personal and family medical history and will have blood drawn. About 1 to 2 tablespoons of blood will be drawn in adults, and about 1 teaspoon in children. The blood will be analyzed for genes that cause GPS
Details: Patients with Gray Platelet Syndrome (GPS) and their unaffected family members will be studied to identify the gene(s) involved in GPS using linkage analysis and gene mapping strategies. Up to 80 individual members of GPS families will be investigated to identify candidate regions of human genome, which will be further studied using fine mapping and sequence analysis. Characterization of gene(s) involved in GPS could provide important insight into the mechanisms of vesicle formation and protein sorting in human cells.
Eligibility:
Study Type: Observational, Natural History
Minimum Age/Maximum Age: /
Genders: Both
Protocol Entry Criteria: INCLUSION CRITERIA: Enrollment in this study will be limited to patients diagnosed with GPS and their unaffected relatives. The diagnosis will be based upon absence or marked reduction of platelet Alpha-granules on electron microscopy. EXCLUSION CRITERIA: Patients with reduction in both Alpha and Beta granules will be excluded, since this is probably a separate disease.
Total Enrollment: 80
Location and Contact Information:
National Human Genome Research Institute (NHGRI) *Recruiting*
Bethesda, Maryland, 20892
United States
Recruiting Patient and Public Liaison Office 1-800-411-1222
Additional Information:
Study ID Numbers: 030313; 03-HG-0313
Study Start Date: September 25, 2003
Record last reviewed: September 23, 2003
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00069680
Other Myelofibrosis Studies:
1. Genetic Analysis of Gray Platelet Syndrome
Related Studies:
Other Myelofibrosis Clinical Trials
Other Maryland Clinical Trials
Other Bethesda Clinical Trials
Genetic Analysis of Gray Platelet Syndrome
|
|
|
|
|
|
|
|
